nach oben

Current Treatment Options in Oncology

Erschienen in:

06.07.2022 | Gynecologic Cancers (JS Ferriss, Section Editor)

Incorporating Molecular Diagnostics into Treatment Paradigms for Endometrial Cancer

verfasst von: Brenna E. Swift, MD, MASc, Lilian T. Gien, MD, MSc

Erschienen in: Current Treatment Options in Oncology | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Opinion statement

The treatment of endometrial cancer has recently undergone a paradigm shift from using traditional clinical-pathologic factors to molecular characterization for prognosis and selection of treatment. Recent approval of pembrolizumab, dostarlimab, and the combination of lenvatinib and pembrolizumab has drastically changed the treatment options and response rate for advanced and recurrent endometrial cancer, especially for DNA mismatch repair–deficient (MMRd) tumors. For p53 abnormal tumors, which have the worst prognosis, there are several new treatment approaches including lenvatinib and pembrolizumab, trastuzumab, and possibly a future role for PARP inhibitors in the homologous recombination deficiency (HRD) p53 abnormal population. In DNA polymerase epsilon–mutated (POLEmut) tumors which have an excellent prognosis, there’s a possibility to de-escalate treatment, and in the small chance of recurrence, these tumors may be susceptible to immune checkpoint inhibitors. Further research is needed to better characterize biomarkers for prognosis and identify targeted treatments within the p53 wild-type (p53 WT)/no specific molecular profile (NSMP) cohort. Upcoming studies are evaluating adjuvant treatment by molecular subtype and will determine the next steps for precision medicine in endometrial cancer.

Getz G, Gabriel SB, Cibulskis K, Lander E, Sivachenko A, Sougnez C, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.CrossRef

Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113(2):299–310.PubMedPubMedCentralCrossRef

Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017;123(5):802–13.PubMedCrossRef

Leon-Castillo A, Horeweg N, Peters EEM, Rutten T, ter Haar N, VTHBM S, et al. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment. Gynecol Oncol [Internet]. 2022;164(3):577–86. https://doi.org/10.1016/j.ygyno.2022.01.007.PubMedCrossRef

León-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, et al. Molecular classification of the PORTEC-3 Trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol. 2020;38(29):3388–97.PubMedPubMedCentralCrossRef

Prendergast EN, Holman LL, Liu AY, Lai TS, Campos MP, Fahey JN, et al. Comprehensive genomic profiling of recurrent endometrial cancer: implications for selection of systemic therapy. Gynecol Oncol. 2019;154(3):461–6.PubMedPubMedCentralCrossRef

Soumerai TE, Donoghue MTA, Bandlamudi C, Srinivasan P, Chang MT, Zamarin D, et al. Clinical utility of prospective molecular characterization in advanced endometrial cancer. Clin Cancer Res. 2018;24(23):5939–47.PubMedPubMedCentralCrossRef

• McAlpine JN, Chiu DS, Nout RA, Church DN, Schmidt P, Lam S, et al. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: an individual patient data meta-analysis. Cancer. 2021;127(14):2409–22. Meta-analysis of 359 women with POLEmut endometrial cancer. Disease progression and recurrence were rare and traditional prognosticators were not associated with disease progression and recurrencePubMedCrossRef

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(8):1114–26.PubMedCrossRef

10.

Van Den Heerik ASVM, Horeweg N, Nout RA, Lutgens LCHW, Van Der Steen-Banasik EM, Westerveld GH, et al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer. 2020;30(12):2002–7.PubMedPubMedCentralCrossRef

11.

Creutzberg C. PORTEC-4a: Molecular profile–based versus standard adjuvant radiotherapy in endometrial cancer (PORTEC-4a) NCT03469674 [Internet]. [cited 2022 Jun 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT03469674

12.

McAlpine J. Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype Early Stage Endometrial Cancer (TAPER) [Internet]. [cited 2022 Jun 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT04705649

13.

Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, et al. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. JAMA Oncol. 2019;5(10):1504–6.PubMedPubMedCentralCrossRef

14.

Mehnert JM, Panda A, Zhong H, Hirshfield K, Damare S, Lane K, et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest. 2016;126(6):2334–40.PubMedPubMedCentralCrossRef

15.

Garmezy B, Gheeya J, Lin HY, Huang Y, Kim T, Jiang X, et al. Clinical and molecular characterization of POLE mutations as predictive biomarkers of response to immune checkpoint inhibitors in advanced cancers . JCO Precis Oncol. 2022;(6):e2100267.

16.

Veneris JT, Lee EK, Goebel EA, Nucci MR, Lindeman N, Horowitz NS, et al. Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. Gynecol Oncol. 2019;153(3):471–8.PubMedCrossRef

17.

Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016;22(11):1342–50.PubMedCrossRef

18.

Kim SR, Pina A, Albert A, McAlpine J, Wolber R, Blake Gilks C, et al. Does MMR status in endometrial cancer influence response to adjuvant therapy? Gynecol Oncol. 2018;151(1):76–81.PubMedCrossRef

19.

McEachron J, Zhou N, Spencer C, Chatterton C, Shanahan L, Katz J, et al. Adjuvant chemoradiation associated with improved outcomes in patients with microsatellite instability-high advanced endometrial carcinoma. Int J Gynecol Cancer. 2021;31(2):203–8.PubMedCrossRef

20.

Reijnen C, Küsters-Vandevelde HVN, Prinsen CF, Massuger LFAG, Snijders MPML, Kommoss S, et al. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. Gynecol Oncol. 2019;154(1):124–30.PubMedCrossRef

21.

Green AK, Feinberg J, Makker V. A review of immune checkpoint blockade therapy in endometrial cancer. Am Soc Clin Oncol Educ B. 2020;40:238–44.CrossRef

22.

•• O’Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus AA, et al. Pembrolizumab in patients with microsatellite instability–high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol. 2022;40(7):752–61. KEYNOTE-158 was a phase II, single-arm trial of pembrolizumab in patients with MMRd advanced endometrial cancer showing ORR of 48%, median PFS of 13.1 months, and median OS not reachedPubMedCrossRef

23.

•• Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET - a phase I, sin. J Immunother Cancer. 2022;10(1):1–10. GARNET was a phase I, single-arm trial of dostarlimab in MMRd and MMRp in advanced and recurrent endometrial cancer showing ORR of 43.5% in MMRd, median PFS of 12.2 months, and median OS not reachedCrossRef

24.

Tamura K, Hasegawa K, Katsumata N, Matsumoto K, Mukai H, Takahashi S, et al. Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: multicenter, open-label phase 2 trial. Cancer Sci. 2019;110(9):2894–904.PubMedPubMedCentralCrossRef

25.

Antill Y, Kok PS, Robledo K, Yip S, Cummins M, Smith D, et al. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. J Immunother Cancer. 2021;9(6):1–8.CrossRef

26.

Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent / persistent endometrial cancer. J Clin Oncol. 2019;37(30):2786–94.

27.

Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, et al. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. Cancer. 2022;128(6):1206–18.PubMedCrossRef

28.

NRG Oncology. Testing the addition of the immunotherapy drug, pembrolizumab, to the usual radiation treatment for newly diagnosed early stage high intermediate risk endometrial cancer [Internet]. [cited 2022 Jun 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT04214067

29.

NRG Oncology. Testing the addition of the immunotherapy drug pembrolizumab to the usual chemotherapy treatment (paclitaxel and carboplatin) in stage III-IV or recurrent endometrial cancer [Internet]. [cited 2022 Jun 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT03914612

30.

ENGOT, GOG. A study to evaluate dostarlimab plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in participants with recurrent or primary advanced endometrial cancer (RUBY) [Internet]. [cited 2022 Jun 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT03981796

31.

Jamieson A, Bosse T, McAlpine JN. The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer. Ther Adv Med Oncol. 2021;13:1–14.CrossRef

32.

•• Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437–48. KEYNOTE-775 was a phase III RCT of lenvatinib and pembrolizumab in MMRp and MMRd advanced endometrial cancer. In the MMRp cohort, the ORR was 30.3%, the median PFS was 6.6 months, and the median OS was 17.4 monthsPubMedCrossRef

33.

Marth C, Tarnawski R, Tyulyandina A, Pignata S, Gilbert L, Kaen D, et al. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. Int J Gynecol Cancer. 2022;32(1):93–100.PubMedCrossRef

34.

Fader A, Roque D, Siegel E, Buza N, Hui P, Abdelghany O, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol. 2018;10(36):2044–51.CrossRef

35.

• Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, et al. Randomized phase II trial of carboplatin–paclitaxel compared with carboplatin–paclitaxel–trastuzumab in advanced (stage III–IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res. 2020;26(15):3928–35. This is a phase II RCT in advanced or recurrent HER2/neu overexpressing uterine serous carcinoma that demonstrated combination of carboplatin-paclitaxel-trastuzumab had a median PFS of 12.9 months and median OS of 29.6 months. There was even greater benefit when trastuzumab was combined with first-line chemotherapy in stage III/IV disease with a median PFS of 17.7 months and median OS not reachedPubMedPubMedCentralCrossRef

36.

Erickson BK, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M, et al. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study. Gynecol Oncol. 2020;159(1):17–22.PubMedPubMedCentralCrossRef

37.

Vermij L, Horeweg N, Leon-castillo A, Rutten TA, Mileshkin LR, Mackay HJ, et al. HER2 status in high-risk endometrial cancers (PORTEC-3): relationship with histotype, molecular classification, and clinical outcomes. Cancers (Basel). 2021;13(22):1–14.

38.

Ingelheim B. A phase II evaluation of afatinibin patients with persistent or recurrent HER2-positive uterine serous carcinoma (afatinib) [Internet]. [cited 2022 Jun 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02491099

39.

NRG Oncology. Testing the addition of trastuzumab or trastuzumab/pertuzumab to the usual chemotherapy for HER2 positive endometrial serous carcinoma or carcinosarcoma [Internet]. [cited 2022 Jun 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT05256225

40.

Liu JF, Xiong N, Campos SM, Wright AA, Krasner C, Schumer S, et al. Phase II study of the WEE1 inhibitor adavosertib in recurrent uterine serous carcinoma. J Clin Oncol. 2021;39(14):1531–9.PubMedCrossRef

41.

De Jonge MM, Auguste A, Van Wijk LM, Schouten PC, Meijers M, Ter Haar NT, et al. Frequent homologous recombination deficiency in high-grade endometrial carcinomas. Clin Cancer Res. 2019;25(3):1087–97.PubMedCrossRef

42.

Post CCB, Westermann AM, Boere IA, Witteveen PO, Ottevanger PB, Sonke GS, et al. Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial). Gynecol Oncol [Internet]. 2022;165(2):223–229. Available from: https://doi.org/10.1016/j.ygyno.2022.02.025

43.

NRG Oncology. Testing the combination of olaparib and durvalumab, cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in recurrent or refractory endometrial cancer following the earlier phase of the study that tested olaparib and cediranib in compa [Internet]. [cited 2022 Jun 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT03660826

44.

Frimer M. Trial of maintenance with niraparib- uterine serous carcinoma [Internet]. [cited 2022 Jun 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT04080284

45.

Squibb B-M, Inc CO. Rucaparib and nivolumab in patients with prostate or endometrial cancer [Internet]. [cited 2022 Jun 1]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03572478

46.

Tesaro. Study of niraparib and TSR-042 in recurrent endometrial cancero Title [Internet]. [cited 2022 Jun 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT03016338

47.

Pfizer. Avelumab in patients with MSS, MSI-H and POLE-mutated recurrent or persistent endometrial cancer and of avelumab/talazoparib and avelumab/axitinib in patients with MSS recurrent or persistent endometrial cancer [Internet]. [cited 2022 Jun 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02912572

48.

Karnezis AN, Leung S, Magrill J, McConechy MK, Yang W, Chow C, et al. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. J Pathol Clin Res. 2017;3(4):279–93.PubMedPubMedCentralCrossRef

49.

Travaglino A, Raffone A, Raimondo D, Reppuccia S, Ruggiero A, Arena A, et al. Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis. Arch Gynecol Obstet [Internet]. 2022;(0123456789). Available from: https://doi.org/10.1007/s00404-021-06385-0

50.

Kommoss FKF, Karnezis AN, Kommoss F, Talhouk A, Taran FA, Staebler A, et al. L1cam further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer. 2018;119(4):480–6.PubMedPubMedCentralCrossRef

51.

Lee SY. Tailored therapy based on molecular characteristics in endometrial cancer. Biomed Res Int. 2021;2021:2068023.

52.

Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011;29(24):3278–85.PubMedPubMedCentralCrossRef

53.

Slomovitz BM, Lu KH, Johnston T, Coleman RL, Munsell M, Broaddus RR, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010;116(23):5415–9.PubMedCrossRef

54.

Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015;33(8):930–6.PubMedPubMedCentralCrossRef

55.

Soliman PT, Westin SN, Iglesias DA, Fellman BM, Yuan Y, Zhang Q, et al. Everolimus, letrozole, and metformin in women with advanced or recurrent endometrioid endometrial cancer: a multi-center, single arm, phase II study. Clin Cancer Res. 2020;26(3):581–7.PubMedCrossRef

56.

Creutzberg C. Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) [Internet]. [cited 2022 Jun 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT05255653

57.

Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223–38.PubMedCrossRef

58.

Orellana TJ, Kim H, Beriwal S, Bhargava R, Berger J, Buckanovich RJ, et al. Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer. Gynecol Oncol [Internet]. 2022;164(1):129–135. Available from: https://doi.org/10.1016/j.ygyno.2021.10.071

59.

Makker V, Taylor MH, Oaknin A, Casado Herraez A, Orlowski R, Dutta L, et al. Characterization and management of adverse reactions in patients with advanced endometrial carcinoma treated with lenvatinib plus pembrolizumab. Oncologist. 2021;26(9):e1599–608.PubMedPubMedCentralCrossRef

60.

Aravantinou-Fatorou A, Andrikopoulou A, Liontos M, Fiste O, Georgakopoulou VE, Dimopoulos MA, et al. Pembrolizumab in endometrial cancer: where we stand now (review). Oncol Lett. 2021;22(6)

Titel: Incorporating Molecular Diagnostics into Treatment Paradigms for Endometrial Cancer
verfasst von: Brenna E. Swift, MD, MASc
Lilian T. Gien, MD, MSc
Publikationsdatum: 06.07.2022
Verlag: Springer US
Erschienen in: Current Treatment Options in Oncology / Ausgabe 8/2022
Print ISSN: 1527-2729
Elektronische ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-022-00993-x

Springer Medizin

Incorporating Molecular Diagnostics into Treatment Paradigms for Endometrial Cancer

Opinion statement

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Opinion statement

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2022

Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer

Metastatic Adenoid Cystic Carcinoma: Genomic Landscape and Emerging Treatments

Correction to: Cardiotoxicity of Systemic Melanoma Treatments

The Role of Immunotherapy in the Treatment of Anal Cancer and Future Strategies

How Genetics Can Drive Initial Therapy Choices for Older Patients with Acute Myeloid Leukemia

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie